Global Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

News provided by

Sep 16, 2021, 09:30 ET

DUBLIN, Sept. 16, 2021 /PRNewswire/ -- Gain comprehensive access to over 1,800 antibody deal records from this report "Global Antibody Partnering Terms and Agreements 2014-2021" that has been added to ResearchAndMarkets.com's offering.

The Global Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,800 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

Global Antibody Partnering Terms and Agreements 2014 to 2021 provides the reader with the following key benefits:

In-depth understanding of Antibody deal trends since 2014
Access to headline, upfront, milestone and royalty data
Detailed access to actual Antibody contracts enter into by the leading twenty five bigpharma companies
Insight into the terms included in a Antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Antibody Partnering Terms and Agreements 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering Terms and Agreements 2014 to 2021 includes:

Trends in Antibody dealmaking in the biopharma industry since 2014
Analysis of Antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 1,800 Antibody online deal records
The leading Antibody deals by value since 2014
Most active Antibody dealmakers since 2014
The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2014 to 2021, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive access to available deals and contract documents for over 1,800 Antibody deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise Antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers
4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory
5.1. Introduction
5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Companies Mentioned

3SBio
4D Pharma
A*STAR Agency for Science
Technology and Research
A*STAR Singapore Immunology Network
Aarhus University Hospital
Abbvie
Abcam
AbCellera
AbCheck
AbClon
Abcuro
Ab E Discovery
Abeome
Abilita Bio
Ab Initio
ABL Bio
Ablexis
Ablynx
AbMed
Abpro
Abveris
Abzena
Acceleron Pharma
Accord Healthcare
Aceno Biotherapeutics
Acerta Pharma
Achaogen
AC Immune
Acticor Biotech
Actinium Pharmaceuticals
Adagene
AdAlta
Adaptimmune
Adaptive Biotechnologies
ADC Therapeutics
Adimab
Adlai Nortye
Aduro BioTech
Advanced Biological Laboratories
Advanced BioScience Laboratories
Advanced Proteome Therapeutics
Advantagene
Advaxis
Aeglea BioTherapeutics
Aevi Genomic Medicine
AffaMed Therapeutics
Affibody
Affilogic
Affimed Therapeutics
Affinita Biotech
AGC Biologics
Agensys
Agenus Bio
Agilvax
AgomAb Therapeutics
AgonOx
AIMM Therapeutics
Aimmune Therapeutics
Akeso Biopharma
Albert Einstein College of Medicine
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Allakos
Allele Biotechnology and Pharmaceuticals
Allergan
Alligator Bioscience
Allogene Therapeutics
Almirall
Alpha Cancer Technologies
Alphamab
Alteogen
Alvogen
Alvotech
Alytas Therapeutics
Amag Pharmaceuticals
Ambrx
American Foundation for AIDS Research (amfAR)
Amgen
Amneal Pharmaceuticals
Amplyx Pharmaceuticals
AnaptysBio
AnGes MG
Angiex
Anthera Pharmaceuticals
Anthos Therapeutics
Antidote Therapeutics
Antigen Express
Antikor Biopharma
Antitope
Apceth
Apeiron Biologics
Aperion Biologics
Apexigen
Aptevo Therapeutics
Aquila BioMedical
Arcus Biosciences
arGEN-X
argenx
Aridis Pharmaceuticals
ARMO Biosciences
Array Biopharma
Arsanis Biosciences
Arsia Therapeutics
Ascenion
Ascentage Pharma
Ascletis
Aslan Pharma
Aspyrian Therapeutics
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Atara Biotherapeutics
aTen Therapeutics
Athenex
Atlab Pharma
Atlangram
Atlante Biotech
Atreca
Austrian Institute of Technology
Avacta
AvantGen
AVEO Oncology
Avid Bioservices
Avidity Biosciences
Avillion
AxioMx
Aytu BioScience
Back-A-Line
Basilea Pharmaceutica
Batavia Biosciences
Bausch & Lomb
Bavarian Nordic
Baxalta
Baxter International
Bayer
Bayer Healthcare
Baylor Institute for Immunology Research
BB100
BeiGene
Benchwise
BerGenBio
Berkeley Lights
Beth Israel Deaconess Medical Center
Biametrics
Bill and Melinda Gates Foundation
Bio-Techne
Bio-Thera Solutions
BioArctic Neuroscience
biOasis Technologies
BioAtla
Biocare Medical
Bioceros
BiocerOX Products
bioCSL
Biocytogen
Biodesix
BioDuro
Biofactura
Bio Farma
Biogen
BioGenes
BioInvent
BioLegend
BiolineRX
bioLytical Laboratories
BioMarker Strategies
Biomax Informatics
Biomedical Advanced Research and Development Authority
Biomedical Catalyst Fund (UK)
Biomunex Pharmaceuticals
BioNovion
BioNTech
Biooutsource
BioRap Technologies
Biosceptre International
Biotem
Biothera
Biotheus
BioTie Therapies
BioVectra
BioVendor
Bioventix
BioWa
BioXcel
BliNK Biomedical
BliNK Therapeutics
Bliss Biopharmaceutical
Bluebird Bio
Blue Sky Biotech
Boehringer Ingelheim
Bpifrance
Brigham and Women's Hospital
Brii Biosciences
Bristol-Myers Squibb
Broad Institute
C-Bridge Capital
C2N Diagnostics
Caerus Discovery
Caliber Biotherapeutics
California Institute for Biomedical Research
California Institute for Regenerative Medicine
California Stem Cell
Calithera Biosciences
Calixar
Calypso Biotech
Canadian Institutes of Health Research
Cancer Prevention and Research Institute of Texas
Cancer Research Technology
Cancer Research UK
Cantargia
CARB-X
CardiNor
Carlina Technologies
Catalent Pharma Solutions
CBT Pharmaceuticals
CDI Laboratories

For more information about this report visit https://www.researchandmarkets.com/r/5430y

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets